Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
How authorities plan to root out the carcinogenic impurities and what it means for other classes of medicines.
Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say
Pharmaceutical industry officials are promoting the idea of “marrying” the concepts of performance-based approaches and process analytical technology in the draft ICH Q12 guideline. Embedding this idea in ICH Q12 would give industry more flexibility in managing post-approval changes and aligns with the guideline’s concept of lifecycle improvement.
Latest From Manufacturing
Pharmacy petitions for recalls after finding ‘inherent instability’ in antacid that could pose carcinogenic risk.
After discovering one firm suppressed over 4,000 compounded-hormone adverse event reports, agency leans on compounders and outsourcers to improve reporting.
New messaging standard from GS1 would enable industry to sell most returned drugs after November DSCSA deadline without running afoul of the FDA.
FDA proposal would allow traditional compounding from five drug substances based on medical need, but not from another 26.
The public-private partnership has $5.5m for grants to develop continuous manufacturing methods, cell/gene therapy platforms and other biopharmaceutical manufacturing innovations.
Expected flurry of FDA proposals against 503B compounding from bulk drug substances follows vasopressin court ruling.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.